These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24418215)

  • 1. Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress.
    Hartner A; Cordasic N; Klanke B; Menendez-Castro C; Veelken R; Schmieder RE; Hilgers KF
    Biochim Biophys Acta; 2014 Apr; 1842(4):558-65. PubMed ID: 24418215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
    Anjaneyulu M; Chopra K
    Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
    Ge J; Miao JJ; Sun XY; Yu JY
    J Ethnopharmacol; 2016 Aug; 189():238-49. PubMed ID: 27224243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irbesartan ameliorates diabetic cardiomyopathy by regulating protein kinase D and ER stress activation in a type 2 diabetes rat model.
    Liu X; Xu Q; Wang X; Zhao Z; Zhang L; Zhong L; Li L; Kang W; Zhang Y; Ge Z
    Pharmacol Res; 2015 Mar; 93():43-51. PubMed ID: 25617729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of angiotensin II receptor antagonist on rat podocyte injury in early diabetic nephropathy].
    Long HB; Zhong J; Wei LB; Zhou WD; Xu ZZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Apr; 27(4):505-8. PubMed ID: 17545045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
    Ren X; Guan G; Liu G; Liu G
    Pharmacology; 2009; 83(2):80-7. PubMed ID: 19065061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on streptozotocin-induced diabetic nephropathy.
    Sen S; Kanter M; Ustundag S; Aktas C; Dogutan H; Yalcin O
    Ren Fail; 2008; 30(10):1023-33. PubMed ID: 19016156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
    Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
    Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy.
    Tunçdemir M; Oztürk M
    Acta Histochem; 2011 Dec; 113(8):826-32. PubMed ID: 21269661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice.
    Lakshmanan AP; Thandavarayan RA; Palaniyandi SS; Sari FR; Meilei H; Giridharan VV; Soetikno V; Suzuki K; Kodama M; Watanabe K
    Eur J Pharm Sci; 2011 Dec; 44(5):627-34. PubMed ID: 22033153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
    Wang ZS; Xiong F; Xie XH; Chen D; Pan JH; Cheng L
    BMC Nephrol; 2015 Mar; 16():44. PubMed ID: 25886386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.
    Janiak P; Bidouard JP; Cadrouvele C; Poirier B; Gouraud L; Grataloup Y; Pierre F; Bruneval P; O'Connor SE; Herbert JM
    Eur J Pharmacol; 2006 Mar; 534(1-3):271-9. PubMed ID: 16516882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
    McMullan CJ; Lambers Heerspink HJ; Parving HH; Dwyer JP; Forman JP; de Zeeuw D
    Am J Kidney Dis; 2014 Nov; 64(5):714-22. PubMed ID: 25064674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of irbesartan on renal advanced glycation end products and their receptor in rats with early diabetic nephropathy].
    Long HB; Niu HX; Li XY; Zhou WD; He JH; Zhong J; Wei LB
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Dec; 29(12):2433-6, 2441. PubMed ID: 20034895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
    Li S; Cao B; Feng QH; Li XZ
    Zhonghua Er Ke Za Zhi; 2003 Nov; 41(11):817-21. PubMed ID: 14728886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
    Abdel-Wahab AF; Bamagous GA; Al-Harizy RM; ElSawy NA; Shahzad N; Ibrahim IA; Ghamdi SSA
    Biomed Pharmacother; 2018 Jul; 103():59-66. PubMed ID: 29635129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?
    Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL
    Clin J Am Soc Nephrol; 2017 Oct; 12(10):1595-1600. PubMed ID: 28923834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the Ku70 and apoptosis-related proteins in experimental diabetic nephropathy.
    Tunçdemir M; Öztürk M
    Metabolism; 2016 Oct; 65(10):1466-77. PubMed ID: 27621182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.